Atacicept R&D Cost Gone, ZymoGenetics Makes Plans
This article was originally published in The Pink Sheet Daily
Executive Summary
Recothrom launch gains momentum as P&T committees meet, GPO deals are forged.You may also be interested in...
Refocusing ZymoGenetics Cuts Staff, Seeds Pipeline Of Private Startup Firm
Refocusing ZymoGenetics Cuts Staff, Seeds Pipeline Of Private Startup Firm
Co-Development Deal Brings Bristol A Novel Interferon, ZymoGenetics Much-Needed Cash
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: